C (CAST ) is the endogenous inhibitor of et al. [5] , in fact, could show an inhibitory effect of calpastatin autoantibodies on calpastatin in vitro. A the intracellular, calcium-activated cysteine proteases very high prevalence of anti-calpastatin autoantibodies calpain I and II ( EC 3.4.22.17) . These enzymes are of 50% has been reported by two groups in RA ubiquitously expressed and show a wide substrate patients [5, 6 ] . This observation could be of importance specificity in vitro. Even though our knowledge regardfor an improved laboratory diagnosis of RA as well ing their physiological role is far from comprehensive, as for understanding the pathophysiology of the dislimited proteolysis by calpains is implicated in numerease. The potential implications of anti-calpastatin ous cellular regulatory processes. These include cytoautoantibodies in RA have been reviewed [9] . skeletal rearrangements in the early phase of platelet
We also recently described the identification of antiaggregation and modulation of intracellular signalling calpastatin autoantibodies, characterized the epitope cascades. Calpain is activated in response to increased and developed a specific peptide enzyme-linked calcium concentration, probably by autocatalytic proimmunosorbent assay ( ELISA) based on the cesses and membrane translocation. Calpastatin is the C-terminal 27 amino acids of calpastatin [7] . Our main most potent known inhibitor of calpain activity and is focus was initially on patients with venous thrombosis probably intimately involved in the regulation of the because of the diagnosis of our first patient with calpain system (for a review, see [1, 2] ).
anti-calpastatin autoantibodies. With the ELISA, a Interestingly, anti-calpastatin autoantibodies have significantly elevated frequency of anti-calpastatin recently been identified by several groups independautoantibodies could be shown in patients with venous ently [3] [4] [5] [6] [7] [8] . The autoantibodies were detected in inferthrombotic events compared to normal controls [8] . tile patients [3, 4] , in patients with rheumatoid arthritis Preliminary analysis of sera from RA patients using (RA) [5, 6 ] and in patients with venous thrombosis the ELISA revealed a low or only slightly increased [8] . One could hypothesize that autoantibodyprevalence of anti-calpastatin autoantibodies. Similar mediated inhibition of the protease inhibitor calpastaresults were obtained by Western blot using a recomtin might lead to unbalanced activation of the proteases binant calpastatin fragment representing amino acids and subsequently to specific disease processes. Mimori 612-708 of calpastatin. The simplest explanation for this apparent discrepancy would be that the calpastatin Mannheim, Germany) was used instead of Vent polymerase and added before the first denaturation step. female) were collected and stored at −20°C. The mean age of this group was 26 yr (.. 6 yr, range 18-55 yr).
For expression of the recombinant proteins, the inserts were subcloned into pXa1 [13] . Expression of the b-galactosidase fusion proteins was carried out as Preparation of lymphocyte RNA Peripheral blood mononuclear cells were collected recently described [7] . In brief, Escherichia coli XL1blue [14] were transformed with the recombinant by means of a cell separator. These cells were further processed by centrifugation in an elutriator as pXa1 constructs. Transformants were grown at 37°C until the OD600 reached 0.4-0.6 and induced with described [11] and the lymphocyte-enriched fractions (>95% purity) were pooled, concentrated and washed.
2 m isopropyl-b--thiogalactopyranoside (IPTG) for Total RNA was isolated using the isothiocyanate/ primers CAST1249-BamHI (5∞-ctaggatccCGGAGTG 3-5 h. Cells were lysed and the crude extracts were previously in several cell types and tissues [16 ] . Otherwise, there were no differences in this fragment analysed by 7.5% SDS-PAGE. and the sequence deposited in the GDB databank (accession number D16217). The second clone with
Immunological assays
Western blot analyses were performed as described the C-terminal region (amino acids 188-708) was also amplified and sequenced. Its sequence was identical to [7] . Briefly, total protein of recombinant E. coli was separated by SDS-PAGE and semi-dry blotted on the above-mentioned databank entry, except for a G1937A transition which would result in an amino polyvinylidene fluoride (PVDF ) membranes. After blocking with milk powder in phosphate-buffered acid exchange Glu592 to Gly. Furthermore, the 3∞-untranslated end of calpastatin was 422 bp longer saline, membranes were incubated with the sera in a dilution of 1:100. Bound IgG were detected using than expected. Both differences to the databank entry have previously been reported [5, 6 ] . The two calpastaperoxidase-coupled anti-human IgG. For screening procedures, membranes were cut into strips tin fragments were isolated from pUC18 and ligated at the SacI restriction site at position 1082, as described (0.5 × 6 cm) and incubated in 2 ml diluted serum. Calpastatin-specific monoclonal antibodies CSF 1-2, in Method, to obtain a full-length calpastatin cDNA which was again verified by sequence analysis. CSL [1] [2] [3] [4] [5] (Dianova, Raboisen, Germany) were used for Western blot analyses at a concentration of 0.1 mg/ml. As a secondary antibody,
Expression of the recombinant proteins
The calpastatin fragments (CAST1-370 and an anti-mouse IgG conjugated to peroxidase (Dianova) was used at 0.8 mg/ml.
CAST188-708), whole calpastatin cDNA and PCRgenerated subfragments were cloned into the expresAll patient and control sera were tested twice on each substrate. A serum was regarded positive if an sion vector pXa1, resulting in an overexpressed bgalactosidase fusion protein when cultured and induced immunoreactive band of the expected molecular weight was detectable. When the results were discordant for in E. coli XL1 blue. A schematic overview of the expressed clones is shown in Fig. 1 . In general, smaller a given serum, the assay was repeated and the result of this third test was the one recorded. Positive reacting fusion proteins were synthesized in larger amounts. Coomassie staining after SDS-PAGE of bacterial lyssera were tested for anti-b-galactosidase reactivity as described [7] , to exclude non-specific binding to ates with the overexpressed fusion proteins often showed additional smaller fragments besides the b-galactosidase.
The anti-calpastatin ELISA has been described in expected bands. This is probably due to incomplete synthesis or degradation of fusion proteins, as indidetail recently. Specifically reacting IgG against the C-terminal calpastatin fragment (peptide 682-708) can cated by Western blots with monoclonal antibodies or calpastatin reactive sera (see below). be detected and quantified with this assay. The results are expressed in arbitrary units. Values >30 U are considered positive [7] . The assay was provided by
Calpastatin fusion proteins stained in Western blotting In Fig. 1 , the domain structure of calpastatin is Progen Biotechnik GmbH, Heidelberg, Germany.
shown and the relative position of the expressed calpas-RESULTS tatin fragments. Figure 1 also illustrates the size of cDNA expression clones shown to react with sera from Analysis of RA sera by ELISA When the sera of 45 RA patients were analysed by RA patients by Mimori et al. [5] and Després et al. [6 ] , both including the C-terminus (domains III and a previously described ELISA [7] for the presence of anti-calpastatin autoantibodies, only four sera (8.9%) IV ) of the protease inhibitor, with 178 and 284 amino acids, respectively. The initial clone found by our were above the cut-off of the assay. This was not significantly different from the frequency of positive group (CAST612-708) is somewhat smaller (97 amino acids), but also contains the C-terminus. sera in healthy control persons, which is~3.4% [7] . Since the assay detects only antibodies against the Expression of calpastatin or calpastatin fragments was demonstrated by Western blots with commercially C-terminal 27 amino acids of calpastatin, the presence of other potentially relevant epitopes in the calpastatin available mouse monoclonal antibodies reactive against human calpastatin. As shown in Fig. 2 , the molecule was investigated.
monoclonal antibody (mAb) clone CSL 5-10 reacted with the whole calpastatin molecule , as Isolation of a full-length calpastatin cDNA by RT/PCR expected, with CAST188-708 and with CAST363-622.
No binding occurred to CAST1-370. The multiple Oligonucleotides were designed to amplify calpastatin from reverse-transcribed lymphocyte RNA. Two bands observed in the Western blot are probably due to incomplete synthesis or degradation of the fusion partial, overlapping calpastatin fragments were generated, and cloned into pUC18 for sequence verification.
protein, since it is never observed with sera binding the C-terminal epitope. The other two mAbs showed Amplification of the N-terminal part of calpastatin (amino acids 1-370) yielded a DNA fragment which different binding sites. When the available information, which indicated that CSF 1-2 bound in calpastatin lacked exon 3 (bases 184-249 coding for amino acids 8-29). Even though this splice variant has not been domain I, CSL 1-5 in domain III, and CSL 5-10 either in domain II or domain IV, was combined with described in lymphocytes as yet, it has been detected our own Western blot data, the binding regions of the there is more than one epitope for autoantibodies within calpastatin. three mAbs used could be narrowed to the following regions (see also Fig. 1 
): CSF 1-2 binds within amino acids 150-188 of calpastatin, CSL 1-5 binds within
Western blot screening with sera from RA patients and normal controls amino acids 427-563 and CSL 5-10 binds within amino acids 363-426.
Sera from patients with RA were analysed in order to obtain data on the prevalence of autoantibodies Western blots with different calpastatin reactive sera are also shown in Fig. 2 . The serum of patient H.M., against calpastatin in these patients. The mean age of the RA patients was 56.7 yr, ranging from 28 to 84 yr. in whom the initial calpastatin autoantibody was identified, binds to the C-terminal cDNA clone There were 36 women and nine men. Approximately 55% (25) tested positive for rheumatoid factor, and 29 (CAST612-708), to whole calpastatin and to the C-terminal part (CAST188-708), but shows only had elevated C-reactive protein (>8 mg/l ), indicative of active disease. Of these, 17 had C-reactive protein a weak reaction with the N-terminal clone CAST1-370 and no binding to the fragment CAST363-622. This levels >20 mg/l and 11 had levels >50 mg/l. In a first step, sera from 45 RA patients and is consistent with the data published earlier where the epitope of this patient's calpastatin-reactive IgGs could 20 controls were tested for reactivity against b-galactosidase fusion proteins containing amino acids be localized to the very C-terminus [7] .
A further example demonstrates calpastatin-specific 1-370 (CAST1-370) or amino acids 188-708 (CAST188-708) (Fig. 3) . Among the RA sera, 34/45 binding to at least two different epitopes: serum of a patient with systemic lupus erythematosus (SLE) (B6) (75.6%) reacted against CAST1-370 and 20/45 (44.4%) reacted against CAST188-708. However, 13/20 recognizes the N-terminal fragment (CAST1-370) and CAST612-708. It should be noted that this serum also (65.0%) control sera also reacted against CAST1-370 and 11/20 (55.0%) against CAST188-708, so that there does not bind to peptide 363-622.
The Western blot results with an RA serum was no significant difference between both groups ( Table I ). (RAR390) are shown as an example for a calpastatinpositive serum which does not recognize the C-terminal Thereafter, the C-terminal half of calpastatin was analysed, since this region had been described previepitope. Typical are the double bands in the first two lanes from the left with whole calpastatin and ously as a highly prevalent autoantigen in RA patients [5, 6 ] . Two different calpastatin clones, namely CAST188-708. The lower bands represent incomplete or degraded fusion proteins, which apparently do not CAST363-622 and CAST612-708 (initial clone), were used as antigens in Western blot assays with all 45 RA bind sera which are reactive against the C-terminus only (see above). These data clearly demonstrate that sera and 52 sera from healthy blood donors. A total Fig. 1 ). It should be noted that RA42 is positive against both fusion proteins typically seen if binding autoantibodies with reactivity against the C-terminal 27 amino acids, is in the overlapping region of both clones. as in patient H.M., do not produce multiple bands with a lower molecular weight than the intact fusion protein as seen with antibod- Table II ). Even though there was a trend for a higher ies with a more N-terminal binding site including the mAb CSL frequency of autoantibodies in the anti-calpastatin 5-10. This is also true for patient B6 who has an antibody against ELISA, the observed frequency of anti-calpastatinthe C-terminal epitope confirmed by ELISA and an antibody to the positive sera in RA patients is not significantly different N-terminal half of calpastatin. It is assumed that the additional bands represent incompletely synthesized or degraded fusion protein.
from that in normal controls (7/205, 3.4%). However, Sera: H.M., initial patient; B6, patient with SLE; RAR390, RA when the clinical records of the four RA patients with patient; CSL 5-10, monoclonal antibody.
positive anti-calpastatin titres were analysed, all four had severely increased C-reactive protein ( Table II ) . In fact, all four were in the highest quartile for of five RA sera (11.1%) and four normal control sera C-reactive protein. (7.7%) showed autoreactivity against either one of the When the N-terminal part of calpastatin was anatwo autoantigens. Two RA and control sera each lysed, a high prevalence of autoantibodies was detected reacted against CAST363-622, while three RA sera both in RA and normal sera, as described above. and two control sera reacted against CAST612-708.
Using subclones for the region between amino acids 1 None of the positive sera reacted against and 370 ( Fig. 1) , it could be shown that~42% (19/45) b-galactosidase alone.
of RA sera recognized CAST1-188 (Table I ). An As expected from our previous data, all sera which bound to CAST612-708 also reacted with the very The most striking association of calpastatin antibodies also observed in patients with other underlying diswith~50% positive sera was reported independently orders ( Fig. 4) . The very high frequency of antiby two groups in patients with RA [5, 6 ] . Both calpastatin autoantibodies reactive against the investigations were based on the detection of autoanti-N-terminal half of calpastatin in RA sera was similar bodies by Western blotting patient sera against recomto that observed in other studies using a C-terminal binant calpastatin fusion proteins. In one study, the epitope. However, normal controls also showed a fusion protein contained amino acids 425-708 of calpacomparably high prevalence of anti-calpastatin autostatin connected to glutathione-S-transferase [6 ], in antibodies: six out of 20 sera (30.0%) and seven out the other amino acids 531-708 of calpastatin fused to of 20 (35.0%) bound to the calpastatin regions 1-188 b-galactosidase [5] . Després et al. [6 ] reported that and 334-369, respectively. In summary, 34 out of 45 none of 10 control sera reacted in the Western blot sera (75.6%) from RA patients and 13 out of 20 sera assay, while Mimori et al. [5] did not report any data (65.0%) from normal controls reacted specifically with on healthy controls. The very high frequency of antithe N-terminal 370 amino acids of calpastatin. The calpastatin autoantibodies in RA patients could not difference between RA patients and normal controls is be reproduced in a preliminary analysis of our own not significant, indicating that there is no disease RA patients using an ELISA based on a smaller specificity for these antibodies. At present, it is not antigen [7] . While the prevalence of autoantibodies clear why the N-terminal fusion proteins react with against a fusion protein with amino acids 612-708 was IgG from such a high percentage of sera obtained <10% in RA sera, it was~5% in control sera, from apparently healthy persons.
indicating that calpastatin antibodies directed against Together with the previously described epitope the C-terminus of the protein are not more common (CAST682-708), which represents the peptide used for in RA than in healthy controls. the anti-calpastatin ELISA, two narrow binding This result indicated to us the possibility that the regions of IgG autoantibodies to calpastatin could be relevant epitope recognized by autoantibodies present identified ( Fig. 1) : one between amino acids 334 and in RA sera was different from the C-terminus of the 369, and one at the carboxy-terminal 27 amino acids.
protein. Such an epitope would be expected between Only the latter has been verified using a synthetic amino acids 531 and 612, which represents the region peptide (see also [7] ). Furthermore, there are many of calpastatin contained in the antigens used by both sera with reactivity against amino acids 1-188. other groups, but not in our initial antigen. Unexpectedly, only very few sera bound specifically to Analysis of sera from patients with RA did not amino acids 363-622. support this assumption. Out of 45 sera from RA patients, only five (11.1%) showed reactivity against the C-terminal half of calpastatin (amino acids 363-708). Three of these sera (6.6%) reacted against the previously described C-terminal peptide (amino acids 612-708), while only two (4.5%) reacted against amino acids 363-622. These data indicate that the use of a larger antigen does not lead to a substantially higher prevalence of anti-calpastatin autoantibodies in our RA patients. In fact, the prevalence of autoantibodies binding between amino acids 363 and 622 is again similar in RA patients and healthy controls. Thus, the hypothesis of an 'RA-specific' epitope on calpastatin within the region from amino acid 531 to 612 could not be confirmed. When the whole protein was screened for further major epitopes, two more antigenic regions could be identified. Autoantibodies against these two regions were found by Western blotting in high frequency in patient and control sera. It is unclear why normal sera have such a high prevalence of antibodies against the calpastatin.
This observation underlines the difficulties with in thrombosis patients [8] . The availability of a specific screening patient sera in Western blot assays based on ELISA to detect autoantibodies against this part of recombinant proteins. Depending on the structure of calpastatin will clearly facilitate the analysis of larger the recombinant proteins, there may be a high prevapatient groups. lence of positive sera in the general population. Furthermore, the interpretation of Western blot results A is much more prone to investigator bias than, for This study was supported by a joint research and instance, ELISA readings. Often, non-specific bands development grant from the Bundesministerium fü r with a slightly different apparent molecular weight may Bildung und Forschung (BMBF ), Germany, and be observed. Another problem is the fact that the time Progen Biotechnik GmbH, Heidelberg, Germany. provided for signal development may profoundly influence the appearance of a blot. Therefore, a thorough analysis of control sera under the same experi-R mental conditions is mandatory before any conclusions
